Morepen Laboratories Ltd (MOREPENLAB) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Morepen Laboratories Ltd on NSE and BSE, with an AI summary of each filing.
Change in Senior Management Personnel on account of resignation
Change in Management · 31 Oct 2026, 11:46 pm
Morepen Laboratories Announces Resignation of Head of Corporate Finance & IR Morepen Laboratories Limited announced the resignation of Mr. Nishant Jayesh Doshi, Vice President – Corporate Finance & Investor Relations and Senior Management Personnel, effective 31st Oct'26. Mr. Doshi tendered his resignation after serving the requisite notice period to pursue external professional opportunities.
Change in Designation of Senior Management Personnel of the Company
Change in Management · 28 Oct 2026, 1:13 am
Morepen Laboratories Promotes Senior Management Personnel in Key Operational Roles Morepen Laboratories Limited announced designation changes for key Senior Management Personnel effective 27th Oct'26 following internal promotions. Charanjeet Chitakara has been elevated from General Manager to Assistant Vice President (Quality Control), overseeing Quality Assurance and regulatory compliance. Additionally, Vivan Prashar has been promoted from Assistant Vice President to Vice President (Projects & Engineering) - Operations (API). Both appointments are on a full-time employment basis, reinforcing operational leadership across the company's core API manufacturing and quality control functions.
Please find attached the monitoring agency report for the quarter ended September 30, 2026
Others (Uncategorized) · 27 Oct 2026, 8:48 pm
Morepen Laboratories Releases Monitoring Agency Report for Q2FY27 QIP Proceeds CARE Ratings reported no material deviation in Morepen Laboratories' ₹200.00 crore QIP proceeds utilization for the quarter ended 30th Sep'26. Total net proceeds of ₹189.08 crore saw cumulative deployment of ₹181.10 crore, with ₹1.12 crore utilized in Q2FY27 for modernization and expansion of Baddi units. Working capital funding of ₹66.29 crore stands fully utilized. Unutilized proceeds of ₹7.98 crore remain invested in debt mutual funds and bank balances. Capex completion timelines were extended to 31st Mar'27, with the monitoring agency flagging potential cost overrun risks.
Please find attached the Investor Presentation for Q2 & H1 FY 27 Financial Results
Investor Presentation · 27 Oct 2026, 7:13 pm
Morepen Laboratories Delivers Record Q2 & H1 FY27 Performance Driven by CDMO Scale-Up Morepen Laboratories reported strong Q2 FY27 results, with revenue surging 81% YoY to Rs. 755 Cr, EBITDA jumping 273% YoY to Rs. 132 Cr (margin up 897 bps to 17.45%), and PAT rising 117% YoY to Rs. 89 Cr. Growth was powered by CDMO revenues jumping 4.3x QoQ to Rs. 253 Cr, accounting for 52% of API + CDMO sales. For H1 FY27, revenue reached Rs. 1,330 Cr (+57% YoY) and PAT grew 177% YoY to Rs. 145 Cr, while TTM ROCE and ROE expanded to 18.8% and 13.6%.
Please find attached the press release
Press Release · 27 Oct 2026, 7:09 pm
Morepen Laboratories Reports Record Q2 FY27 Driven by Robust CDMO Scale-Up Morepen Laboratories reported record Q2 FY27 revenue of Rs. 755 Cr, up 81% YoY, with EBITDA surging 273% YoY to Rs. 132 Cr as margins expanded 897 bps to 17.45%. PAT rose 117% YoY to Rs. 89 Cr. Growth was propelled by commercial CDMO scale-up, generating Rs. 253 Cr in Q2 (52% of API+CDMO revenue). Exports jumped 131% to Rs. 397 Cr, and Medical Devices grew 65% to Rs. 208 Cr. API+CDMO capacity reached 614 KL, targeting 800 KL by Q2 FY28.
Please find attached the Q2 & H1 FY 27 Financial Results
Financial Result · 27 Oct 2026, 7:06 pm
Please find attached the Q2 & H1 FY27 Financial Results along with Limited Review Report
Outcome · 27 Oct 2026, 7:03 pm
Morepen Laboratories Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Outcome · 27 Oct 2026, 7:01 pm
Morepen Laboratories Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Lakh) ■ Revenue: 74,650 (+81.4% YoY | +30.9% QoQ) ■ EBITDA: 12,312 (+301.1% YoY | +49.2% QoQ) ■ EBITDA Margin (%): 16.5 (+903 bps YoY | +202 bps QoQ) ■ PAT: 8,889 (+117.5% YoY | +57.6% QoQ) ■ EPS (INR): 1.62 (+116.0% YoY | +57.3% QoQ)
MOREPEN LABORATORIES LIMITED has informed the Exchange about Board Meeting to be held on 27-Oct-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Quarterly ended September 2026 .
Intimation · 27 Oct 2026, 5:30 am
To consider and approve the financial results for the period ended September 30, 2026
Intimation · 27 Oct 2026, 5:30 am
Morepen Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/10/2026 ,inter alia, to consider and approve financial results for ....
Intimation · 27 Oct 2026, 5:30 am
Morepen Laboratories Schedules Board Meeting on 27th Oct'26 for Q2 Earnings Morepen Laboratories Limited has scheduled a Board of Directors meeting for Tuesday, 27th Oct'26, to consider and approve the un-audited standalone and consolidated financial results for the quarter and half year ended 30th Sep'26. In accordance with insider trading regulations, the trading window for designated persons and their immediate relatives remains closed until 48 hours post-declaration of the financial results, concluding on Thursday, 29th Oct'26.
Please find attached the disclosure
Others (Uncategorized) · 14 Oct 2026, 11:44 pm
Morepen Laboratories Secures Relief as High Court Quashes ₹117.94 Cr GST Demand The High Court of Himachal Pradesh, via an order dated 12th Oct'26, quashed a Show Cause Notice issued by the Central GST Commissionerate, Shimla, against Morepen Laboratories Limited. The notice had demanded recovery of ₹117,94,03,452 towards alleged excess GST refund claims alongside applicable interest and penalties. The court ruled in favour of the company, disposing of the writ petition. Consequently, the company confirmed that the order poses zero financial or operational impact on its activities.
Please find attached the press release
Press Release · 28 Sept 2026, 2:23 pm
Morepen Laboratories Submits First U.S. ANDA for Sitagliptin Tablets Morepen Laboratories has filed its first U.S. ANDA (No. 221758) on 25th Sep'26 with the USFDA for Sitagliptin Tablets USP (25 mg, 50 mg, and 100 mg), marking a key shift into integrated finished dosage CDMO services. Sitagliptin, an oral Type 2 diabetes treatment (innovator Januvia), recorded global sales of ~$1.604 billion in '25. The drug's U.S. patent expires on 24th Nov'26, with pediatric exclusivity extending to 24th May'27. Morepen estimates approval and commercial supply within 24–36 months, subject to regulatory reviews and inspections.
Please find attached the Voting Results and the Scrutinizer Report of 41st Annual General Meeting
Annual General Meeting · 27 Sept 2026, 1:35 am
Proceedings of 41st Annual General meeting of the Company
Annual General Meeting · 26 Sept 2026, 11:03 pm
Please find attached the file
Others (Uncategorized) · 22 Sept 2026, 9:40 pm
CRISIL Assigns 'Adequate' ESG Rating of 'CRISIL ESG 60' to Morepen Laboratories Morepen Laboratories received intimation on 21st Sep'26 that Crisil ESG Ratings & Analytics Limited has assigned the company an overall ESG score of 'CRISIL ESG 60', categorizing its performance as 'Adequate'. The assessment was conducted independently by CRISIL based on publicly disclosed information for FY26, without formal engagement from the company.
Business Update-First Phase of Manufacturing Capacity Expansion Completed Ahead of Schedule
Others (Uncategorized) · 07 Sept 2026, 2:23 pm
Morepen Laboratories Completes Phase 1 Capacity Expansion Ahead of Schedule Morepen Laboratories Limited announced on 7th Sep'26 that it has completed the first phase of its manufacturing capacity expansion ahead of schedule. The company's installed reactor capacity for API and CDMO operations expanded from 535 KL to 614 KL. This enhancement strengthens manufacturing readiness for scaling up commercial CDMO supplies, supports the existing API business, and facilitates future customer programs as part of its strategy to build a scalable, globally compliant platform.
Please find attached the specimen letter
Annual Report · 02 Sept 2026, 7:06 pm
Please find attached the BRSR for the financial year ended March 31, 2026
Others (Uncategorized) · 02 Sept 2026, 6:58 pm
Morepen Labs FY26 BRSR: INR 1,676.66Cr Turnover With 9.39% ESG Capex Allocation Morepen Laboratories reported operational turnover of INR 1,676.66 crore and a net worth of INR 1,245.41 crore for the year ended 31st Mar'26. Revenue was primarily driven by the API segment (56.33%) and Medical Devices (35.60%), with exports comprising 40% of total turnover. Highlighting its ESG focus, the company allocated 9.39% of total capex towards environmental initiatives, including a 955-KW solar plant and zero-liquid-discharge systems. Furthermore, Morepen achieved an EcoVadis Bronze Medal (score 70), reinforcing its sustainability profile to support international market expansion.
Please find enclosed notice of 41st AGM scheduled to be held on Saturday 26th September 2026 at 1:00 p.m. through VC/OAVM.
Annual General Meeting · 02 Sept 2026, 6:53 pm
Please find attached the Annual Report for the financial year 2025-26 along with notice of 41st AGM
Others (Uncategorized) · 02 Sept 2026, 6:44 pm
Allotment of equity shares by Morepen RX Limited, wholly owned subsidiary of the company
Others (Uncategorized) · 06 Aug 2026, 10:40 pm
Morepen Labs Invests ₹20 Crore in Subsidiary via Rights Issue On 06 Aug'26, Morepen Laboratories invested ₹20 Crore in its wholly-owned subsidiary, Morepen RX Limited (MRX), by subscribing to 2 crore equity shares at ₹10/share in a rights issue. The cash transaction aims to strengthen MRX's capital base and support its business operations. Post-allotment, Morepen's total shareholding in MRX increased to 2.71 crore shares, maintaining its 100% ownership. For FY26, MRX reported a turnover of ₹54.5 Crore and a net worth of ₹47.72 Lakh.
Please find attached the monitoring agency report for the quarter ended June 30, 2026
Others (Uncategorized) · 04 Aug 2026, 9:16 pm
Morepen Labs: QIP Proceeds Utilization Report for Q1FY27 Morepen Laboratories submitted its monitoring report for the quarter ended 30-Jun'26 regarding its Rs. 200 crore QIP. As of Q1FY27, Rs. 179.98 crore of the net proceeds (Rs. 189.08 crore) have been utilized, leaving Rs. 9.10 crore unutilized. The utilization timeline for capital expenditure has been extended, which may risk cost overruns. The report also highlights subdued profitability from API margin compression and a pending Rs. 117.94 crore GST show-cause notice from FY21-FY24, for which the company has obtained a stay.
41st Annual General Meeting scheduled to be held on September 26, 2026
Annual General Meeting · 04 Aug 2026, 8:03 pm
Re-appointment of Mr. Sushil Suri as Chairman & Managing Director w.e.f. October 20, 2026
Change in Management · 04 Aug 2026, 7:53 pm
Morepen Board Approves Q1FY27 Results and Proposes Dividend and MD Re-appointment Morepen Laboratories’ board approved Q1FY27 results and other key proposals on 04th Aug'26. Consolidated Net Profit grew 422% YoY to Rs. 5,640 Lakhs from Rs. 1,075 Lakhs, while revenue rose 34% YoY to Rs. 57,013 Lakhs. The board set 19th Sep'26 as the record date for the FY26 final dividend. Subject to AGM approval, the company will extend the timeline for hiving off its Medical Devices Business and re-appoint Mr. Sushil Suri as Chairman & MD for three years from 20th Oct'26.